Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Crumpacker

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Annals of Internal Medicine|November 1, 1987
Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferationC Crumpacker, W Heagy, G Bubley, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1994
Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 TeamD Hardy, S Spector, B Polsky, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
Journal of Clinical Microbiology|May 23, 1998
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolatesJ M McSharry, N S Lurain, G L Drusano, et al.
American Journal of Epidemiology|November 1, 1984
A multivariate analysis of risk factors for hepatitis B virus infection among hospital employees screened for vaccinationD R Snydman, A Muñoz, B G Werner, et al.
Science (New York, N.Y.)|March 13, 1987
Ribavirin antagonizes the effect of azidothymidine on HIV replicationM W Vogt, K L Hartshorn, P A Furman, et al.
The New England Journal of Medicine|September 7, 1995
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study GroupW L Drew, D Ives, J P Lalezari, et al.
The Journal of Infectious Diseases|April 14, 2000
Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonateR J Oram, D Marcellino, D Strauss, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2000
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolatesM L Landry, S Stanat, K Biron, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Internal Medicine|November 1, 1987
Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferationC Crumpacker, W Heagy, G Bubley, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 1, 1994
Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 TeamD Hardy, S Spector, B Polsky, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
Journal of Clinical Microbiology|May 23, 1998
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolatesJ M McSharry, N S Lurain, G L Drusano, et al.
American Journal of Epidemiology|November 1, 1984
A multivariate analysis of risk factors for hepatitis B virus infection among hospital employees screened for vaccinationD R Snydman, A Muñoz, B G Werner, et al.
Science (New York, N.Y.)|March 13, 1987
Ribavirin antagonizes the effect of azidothymidine on HIV replicationM W Vogt, K L Hartshorn, P A Furman, et al.
The New England Journal of Medicine|September 7, 1995
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study GroupW L Drew, D Ives, J P Lalezari, et al.
The Journal of Infectious Diseases|April 14, 2000
Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonateR J Oram, D Marcellino, D Strauss, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2000
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolatesM L Landry, S Stanat, K Biron, et al.
Pageof 3